Trial intelligence / Profile preview

Epoetin Alfa in Early Renal Insufficiency (CRETA)

NCT00446576Phase 3Completed

Sponsor
Johnson & Johnson
Start
Nov 1999
Modality
Biologic, rProtein (Recombinant Protein)
01

Overview

A Phase 3 trial of epoetin alfa in anemia of chronic kidney disease (CKD-A), sponsored by Johnson & Johnson. Started Nov 1999; status: completed.

02

Drugs

epoetin alfa
03

Conditions

anemia of chronic kidney disease (CKD-A)

Beyond the preview

Go deeper on NCT00446576.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00446576.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call